Prolia 60mg in Cancer Care
Patient-focused guide to where Prolia 60mg fits in cancer care, how it differs from Xgeva 120mg, and what to ask about bone protection, ONJ risk, and stopping safely.
A guide for people with breast cancer, prostate cancer, and other cancers with bone involvement — including those already metastatic and those at high risk of bone loss.
Prepared for community members to use in conversations with their oncology team.
The big picture — what is Prolia and why are we talking about it?
Prolia is the brand name for denosumab 60 mg.
It is a 6-monthly injection that protects bone by blocking a protein called RANKL.
Think of RANKL as a signal that tells your body to break down bone.
Prolia intercepts that signal before it does damage.
The same active drug, denosumab, also comes in a stronger cancer-specific version called Xgeva.
Xgeva is 120 mg every 4 weeks.
These are not interchangeable.
They are different doses for different situations, and understanding the difference matters when you are talking to your oncologist.
Denosumab works by specifically targeting osteoclasts, the cells that break down bone.
It reduces their number and activity without the same kidney burden seen with many bisphosphonates.
That can make it useful for patients with renal issues.
For the broader comparison between denosumab and zoledronic acid in bone metastases, see Denosumab and Zoledronic Acid.
Prolia 60mg vs Xgeva 120mg — the key difference
This is the question that causes the most confusion in community discussions, and often in oncology clinics too.
Feature | Prolia 60mg | Xgeva 120mg |
|---|---|---|
Approved use in cancer | Bone-loss prevention during aromatase inhibitor or androgen deprivation therapy, in people without active bone metastases | Active bone metastases — preventing fractures, spinal cord compression, pain events, and other skeletal-related events |
Frequency | Every 6 months | Every 4 weeks |
Route | Subcutaneous injection | Subcutaneous injection |
PBS-subsidised in Australia | Yes, in settings such as osteoporosis and some ADT-related bone loss | Yes, for bone metastases from breast cancer and castration-resistant prostate cancer |
ONJ risk | Very low at the 60 mg dose | Meaningfully higher in metastatic patients on prolonged treatment |
Stopping risk | Rebound fracture risk — needs a bisphosphonate transition plan | The same rebound principle applies, though the metastatic context is more complex |
The bottom line is simple.
If cancer has already spread to bone, Xgeva 120 mg is the approved bone-protection version in that setting, not Prolia 60 mg.
Prolia 60 mg is mainly used when bones are at risk from cancer treatment, such as aromatase inhibitors or ADT, but there are not active bone metastases.
Where Prolia 60mg fits in cancer care
Breast cancer — on aromatase inhibitors
If you are postmenopausal with hormone-receptor-positive breast cancer and taking an aromatase inhibitor such as letrozole, anastrozole, or exemestane, you are at real risk of bone loss.
Aromatase inhibitors work partly by reducing oestrogen.
That same oestrogen normally helps protect bone.
The landmark trial here is ABCSG-18.
This was a large double-blind randomised study of more than 3,400 postmenopausal women with hormone-receptor-positive early breast cancer taking aromatase inhibitors.
Adding Prolia 60 mg every 6 months produced several important findings:
about a 50% reduction in fractures compared with placebo
improved disease-free survival
improved bone-metastasis-free survival
improved overall survival in long-term follow-up
at 11 years, disease-free survival of 74.4% in the denosumab arm versus 69.0% in the placebo arm
essentially zero osteonecrosis of the jaw at this dose in that trial setting
These are significant findings.
The lead researcher, Prof Michael Gnant, argued that adjuvant denosumab at 60 mg every 6 months should be considered for routine clinical use in postmenopausal women on aromatase inhibitor therapy.
In practice in Australia, many patients are still not routinely offered this unless bone density is already declining.
Prostate cancer — on androgen deprivation therapy
Men on ADT for non-metastatic prostate cancer also face real bone loss.
ADT works by dramatically lowering testosterone.
Testosterone, including its downstream conversion to oestrogen, helps protect bone mass in men too.
Prolia 60 mg is an approved and accessible option for reducing fracture risk in this setting.
Once prostate cancer has spread to bone, the treatment discussion usually shifts to Xgeva 120 mg every 4 weeks.
The evidence in metastatic castration-resistant prostate cancer shows that cancer-dose denosumab is superior to zoledronic acid in delaying the first serious skeletal-related event.
Other cancers and high fracture risk
For any cancer where treatment such as steroids, chemotherapy, or hormone suppression is causing significant bone loss, and there are no current bone metastases, Prolia 60 mg may be appropriate.
Bone mineral density and fracture risk should still be assessed properly before that decision is made.
If you already have bone metastases — what to ask for
Once cancer is confirmed in bone — whether from breast, prostate, lung, kidney, thyroid, or another solid tumour — the protection needed is much more aggressive.
That is where Xgeva 120 mg every 4 weeks becomes the relevant denosumab schedule.
Large phase 3 trials have shown that Xgeva:
delays the time to first serious bone complication compared with zoledronic acid in metastatic breast cancer
is superior to zoledronic acid in preventing and delaying skeletal-related events in breast cancer
delays pain progression and worsening quality of life from bone disease in some settings
shows non-inferiority or superiority across broader solid-tumour bone-metastasis populations depending on the endpoint
does not require dose adjustment for kidney impairment, unlike IV bisphosphonates
Skeletal-related events are not just fractures.
They also include:
spinal cord compression
the need for radiation to bone
the need for surgery to bone
severe pain events linked to bone disease
In advanced breast cancer, the burden of these events can be substantial without bone protection.
In Australia, Xgeva is PBS-listed for several cancer settings including:
bone metastases from breast cancer
bone metastases from castration-resistant prostate cancer
giant cell tumour of bone
hypercalcaemia of malignancy
Denosumab biosimilars may also improve access options.
The quality-of-life middle way — dose reduction after 1 to 2 years
This is the section many community members are really asking about.
It matters especially to people already living with metastatic disease who are trying to balance bone protection with side effects and treatment burden.
Australia’s eviQ protocols state that evidence beyond two years of denosumab is limited.
They also note that, by expert opinion, clinicians may consider reducing the frequency to every 6 to 12 weeks at their discretion to reduce cumulative exposure and lower risks such as osteonecrosis of the jaw.
This is an important protocol note.
It means an oncologist can reasonably consider spacing out Xgeva after long-term monthly treatment, especially if:
disease is under good control
bone scans are stable
no skeletal-related event has occurred
ONJ risk is rising
treatment burden is becoming a bigger issue
This is not the same as stopping treatment.
It is a dose-spacing discussion.
ONJ — osteonecrosis of the jaw — a reality check
ONJ is the most feared side effect of denosumab.
It deserves a clear and honest discussion.
Risk by dose and indication
Situation | ONJ risk |
|---|---|
Prolia 60 mg for osteoporosis | Very rare in trial settings, though not zero in real-world dental extraction data |
Prolia 60 mg for AI- or ADT-related bone loss | Extremely low in the major cancer-prevention setting, with no confirmed cases in ABCSG-18 |
Xgeva 120 mg every 4 weeks for bone metastases | Much higher, with real-world metastatic studies showing a meaningful cumulative risk over time |
Xgeva followed by bisphosphonates | Highest risk in some observational series |
The risk at 60 mg every 6 months is dramatically lower than at 120 mg every 4 weeks.
At the higher cancer dose, risk rises significantly with time on treatment.
Practical steps to reduce ONJ risk
have a dental check before starting treatment
resolve active decay, gum disease, or infected teeth first
maintain strong oral hygiene throughout treatment
tell your dentist you are on denosumab before any extraction or oral surgery
for Prolia 60 mg, some guidance recommends scheduling invasive dental work just before the next 6-month injection, when suppression is waning
after 1 to 2 years on Xgeva 120 mg, discuss dose spacing if appropriate
if symptoms appear — jaw pain, swelling, exposed bone, loose teeth, numbness — contact the treatment team early
Calcium and vitamin D — non-negotiable companions
Both Prolia and Xgeva suppress bone resorption so effectively that low calcium can become a real problem.
This matters even more in people with:
vitamin D deficiency
heavy bone involvement
poor calcium intake
kidney issues
Key practical points:
calcium and vitamin D are usually needed alongside denosumab
vitamin D should be checked before treatment where possible
marked vitamin D deficiency should be corrected properly
symptoms of low calcium, such as muscle cramps, tingling around the mouth or fingers, or confusion, need prompt medical attention
The stopping problem — why you cannot just walk away
This is critical and still under-discussed.
Denosumab does not stay in bone the way bisphosphonates do.
When it is stopped, the RANKL signal comes back.
Bone resorption can rebound sharply.
That rebound has caused multiple vertebral fractures, sometimes within months of the last dose.
The key message is simple.
Never stop denosumab abruptly without a plan.
If stopping Prolia for osteoporosis or treatment-related bone-loss prevention, the usual principle is to transition to a bisphosphonate around the time the next dose would otherwise have been due.
In metastatic care, the conversation is more nuanced because the rebound risk has to be weighed against the wider cancer context.
But the need for a planned transition still stands.
The Australian context — what your oncologist may or may not offer
Here is the practical picture many patients run into.
What is well established and routinely offered
Xgeva 120 mg every 4 weeks for confirmed bone metastases from breast cancer or castration-resistant prostate cancer
Prolia 60 mg for osteoporosis when standard PBS criteria are met
Prolia 60 mg for some ADT-related bone-loss settings
What is often under-offered or requires patient advocacy
Prolia 60 mg for ER-positive breast cancer patients on aromatase inhibitors, even when the fracture-prevention evidence is strong
discussion of possible disease-outcome benefits from the ABCSG-18 setting
dose spacing of Xgeva after 1 to 2 years of stable metastatic treatment
proactive discussion of the rebound-fracture risk if denosumab ever has to be stopped
Questions worth asking your oncologist
My bone density has declined on aromatase inhibitors. Am I eligible for Prolia?
If I have active bone metastases, should we be discussing Xgeva instead?
I have been on Xgeva for a long time. Is my disease stable enough to discuss spacing it out?
If I ever need to stop denosumab, what is the transition plan?
Should I have a dental check before starting, and how should dental work be timed around injections?
Are my calcium and vitamin D levels being monitored?
Summary for people choosing a quality-of-life-centred path
For community members trying to balance bone protection with treatment burden, the honest picture is:
bone protection is not optional if you have bone metastases, because unmanaged bone disease can lead to fracture, spinal cord compression, severe pain, and major quality-of-life loss
Xgeva 120 mg every 4 weeks is the standard cancer-dose approach, though dose spacing after a stable period may be a reasonable discussion
Prolia 60 mg every 6 months carries far less ONJ risk than cancer-dose denosumab
ONJ at the cancer dose is real, cumulative over time, and worth trying to prevent through dental care and, where appropriate, dose spacing
stopping denosumab without a bisphosphonate bridge can be dangerous because rebound fractures can follow
this is a treatment that needs planning, not casual stopping or drifting off schedule
References from this draft
The original draft pulled from a mix of trial papers, prescribing resources, and patient-facing guidance.
These are the linked sources restored cleanly on this page:
Denosumab versus zoledronic acid in breast cancer with bone metastases
Effects of denosumab versus zoledronic acid on pain in patients with metastatic breast cancer
Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review
These source groups were also part of the original draft and still belong in the evidence base for this page:
Cancer Research UK patient guidance on denosumab, Prolia, and Xgeva
Australian product information, AusPAR, and PBS listing material for denosumab
ABCSG-18 and later long-term follow-up reporting in aromatase-inhibitor-treated early breast cancer
NCI, eviQ, BCNA, RACGP, Macmillan, and related patient or clinical guidance on ONJ risk, calcium support, dose spacing, and stopping safely
Bone metastasis hub pages
Also relevant
Also relevant
This page is educational.
It does not replace oncology, dental, or prescribing advice.
Discuss treatment changes, dose spacing, and stopping plans with your treatment team.
Looking for broader bone-strength support?
Visit the Bone Health hub for practical guidance on:
bone density testing and scan interpretation
lab work, diet, and supplementation
exercise, loading, and safety cautions